Overview

Multiple Sclerosis Drugs Market is poised to register a CAGR of 3.9% during the forecast period 2022 to 2028.

MS is a neurological disorder that causes disability almost universally. Multiple sclerosis is an inflammatory, chronic, and autoimmune disease of the central nervous system that affects the brain's communication with different parts of the body. In this autoimmune disease, the protective myelin sheath surrounding neurons is damaged, causing communication to and from the brain to be disrupted. As a result of such lesions, control of bodily functions is impaired and clinical disabilities may result. A number of types of MS have been recognized, such as relapsing-remitting, clinically isolated syndrome, primary progressive, and secondary progressive, characterized by varying rates of relapses and disability progression. In order to diagnose multiple sclerosis (MS), the majority of evidence comes from clinical findings and supporting tests, such as magnetic resonance imaging (MRI) of the brain and cerebrospinal fluid examination. MS usually develops among young adults between the ages of 29 and 33, and women are more likely to be affected than men. Despite the incomplete understanding of MS etiology, it is interesting to note that the prevalence of MS varies by geography and ethnicity. It has also been suggested that those exposed to adequate sunlight and subsequent production of vitamin D may be less likely to develop multiple sclerosis. Several pharmaceutical companies are currently conducting clinical studies to treat multiple sclerosis. A number of companies are developing new medicines for treating multiple sclerosis radiology, which is helping to drive the market's growth. The high cost of medication used to treat multiple sclerosis (MS) limits the growth of the MS drug market. There is a high risk of impairment associated with multiple sclerosis, which necessitates lifetime therapy.

FutureWise Market Research has illustrated a report on the that provides an in-depth anatomy of Multiple Sclerosis Drugs market trends affecting its growth. Moreover, it includes intricate insights on profitability graph, Multiple Sclerosis Drugs market share, SWOT analysis and geographical augmentation of this business. Furthermore, the report provides information on the status of key market players in the competitive landscape analysis of the market.

The Multiple Sclerosis Drugs market is projected to achieve significant growth by the end of the forecast period as per the research study conducted by FutureWise research analysts. The report explains that this business is predicted to record a remarkable growth rate over the forecast period. This report provides important information regarding the total valuation that this industry holds presently and it also lists the segmentation of the Multiple Sclerosis Drugs market along with the growth opportunities present across this business vertical.

Major players included in the Multiple Sclerosis Drugs market are     

• Biogen 
• Teva Pharmaceutical 
• Merck KGaA 
• Novartis 
• Bayer 
• Sanofi 
• Acorda Therapeutics 
• Questcor Pharmaceuticals 
• Pfizer
• Merck & Co
• F.Hoffmann-La Roche Ltd
• Bristol

(Note: The list of the major players will be updated with the latest market scenario and trends)

Multiple Sclerosis Drugs Market Segmentation:

By Drug Class
• Immunomodulators
• Immunosuppressants
• Interferons
• Others

By Route of Administration
• Oral
• Injection
• Intramuscular
• Subcutaneous
• Intravenous

By Distribution Channel
• Hospital Pharmacy
• Retail Pharmacy
• Online Pharmacy

By Region
• North America
• Europe
• Asia-Pacific
• Latin America
• Middle East and Africa

Multiple Sclerosis Drugs Market Video Sample:

Competitive Landscape:

• Tier 1 players- established companies in the market with a major market share  
• Tier 2 players 
• Emerging players which are growing rapidly 
• New Entrants

FutureWise Key Takeaways:

• Growth prospects
• SWOT analysis
• Key trends
• Key data-points affecting market growth

Objectives of the Study:

• To provide with an exhaustive analysis on the Multiple Sclerosis Drugs market by drug class, by route of administration, by distribution channel and by region
• To cater comprehensive information on factors impacting market growth (drivers, restraints, opportunities, and industry-specific restraints)
• To evaluate and forecast micro-markets and the overall market
• To predict the market size, in key regions — North America, Europe, Asia Pacific, Latin America and Middle East and Africa.
• To record evaluate and competitive landscape mapping- product launches, technological advancements, mergers and expansions

Flexible Delivery Model:

• We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
• The customization services offered are free of charge with purchase of any license of the report.
• You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents

1. Market Introduction
   1.1. Objectives of the Study 
   1.2. Market Definition 
   1.3. Market Scope 
        1.3.1. Years Considered for the Study
        1.3.2. Market Covered
   1.4. Currency 
   1.5. Limitations 
   1.6. Stakeholders 

2. Research Methodology 
   2.1. Research Data 
        2.1.1. Secondary Data
               2.1.1.1. Key Data from Secondary Sources
        2.1.2. Primary Data
               2.1.2.1. Key Data from Primary Sources
   2.2. Market Size Estimation 
   2.3. Market Breakdown and Data Triangulation 
   2.4. Assumptions for the Study  

3. Executive Summary
   3.1. Market Outlook
   3.2. Segment Outlook
   3.3. Competitive Insights

4. Multiple Sclerosis Drugs Market Variables, Trends & Scope
   4.1. Market Lineage Outlook
   4.2. Penetration and Growth Prospect Mapping
   4.3. Industry Value Chain Analysis
   4.4. Cost Analysis Breakdown
   4.5. Technology Overview
   4.6. Regulatory Framework
        4.6.1. Reimbursement Framework
        4.6.2. Standards and Compliances

5. Market Overview
   5.1. Market Dynamics
        5.1.1. Market Driver Analysis
               5.1.1.1. Increasing focus of Multiple Sclerosis Drugs Market Companies on Brand Protection
               5.1.1.2. Untapped Opportunities in Emerging Regions
        5.1.2. Market Restraint Analysis
               5.1.2.1. High Cost Associated with Implementation of Predictive Analysis
        5.1.3. Industry Challenges
               5.1.3.1. Presence of Ambiguous Regulatory Framework

6. Multiple Sclerosis Drugs Market Analysis Tools
   6.1. Industry Analysis - Porter’s
        6.1.1. Supplier Power
        6.1.2. Buyer Power
        6.1.3. Substitution Threat
        6.1.4. Threat from New Entrants
        6.1.5. Competitive Rivalry
   6.2. Pestel Analysis
        6.2.1. Political Landscape
        6.2.2. Environmental Landscape
        6.2.3. Social Landscape
        6.2.4. Technology Landscape
        6.2.5. Legal Landscape
   6.3. Major Deals And Strategic Alliances Analysis
        6.3.1. Joint Ventures
        6.3.2. Mergers and Acquisitions
        6.3.3. Licensing and Partnership
        6.3.4. Technology Collaborations
        6.3.5. Strategic Divestments
   6.4. Market Entry Strategies
   6.5. Case Studies

7. Multiple Sclerosis Drugs Market, By Drug Class Historical Analysis and Forecast 2022-2028 (USD Million)
     7.1. Immunomodulators
     7.2. Immunosuppressants
     7.3. Interferons
     7.4. Others

8. Multiple Sclerosis Drugs Market, By Route of Administration Historical Analysis and Forecast 2022-2028 (USD Million)  
     8.1. Oral
     8.2. Injection
     8.3. Intramuscular
     8.4. Subcutaneous
     8.5. Intravenous

9. Multiple Sclerosis Drugs Market, By Distribution Channel Historical Analysis and Forecast 2022-2028 (USD Million)  
     9.1. Hospital Pharmacy
     9.2. Retail Pharmacy
     9.3. Online Pharmacy

10. North America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    10.1. Introduction
    10.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          10.2.1. U.S.A
          10.2.2. Canada
          10.2.3. Mexico
    10.3. Market Size (USD Million) Forecast for North America 2022-2028

11. Latin America Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    11.1. Introduction
    11.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          11.2.1. Brazil
          11.2.2. Venezuela
          11.2.3. Argentina
          11.2.4. Rest of Latin America
    11.3. Market Size (USD Million) Forecast for Latin America 2022-2028

12. Europe Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    12.1. Introduction
    12.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          12.2.1. Germany
          12.2.2. U.K         
          12.2.3. France
          12.2.4. Italy
          12.2.5. Spain
          12.2.6. Russia
          12.2.7. Poland
          12.2.8. Rest of Europe
    12.3. Market Size (USD Million) Forecast for Europe 2022-2028

13. Asia Pacific Multiple Sclerosis Drugs Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    13.1. Introduction
    13.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          13.2.1. Japan
          13.2.2. China
          13.2.3. India
          13.2.4. Australia and New Zealand
          13.2.5. ASEAN
          13.2.6. Rest of Asia Pacific
    13.3. Market Size (USD Million) Forecast for Asia Pacific 2022-2028  

14. Middle East and Africa Market Analysis 2016-2020 and Forecast 2022-2028 (USD Million)
    14.1. Introduction
    14.2. Historical Market Size (USD Million) Analysis By Country, 2016-2020
          14.2.1. GCC
          14.2.2. Israel
          14.2.3. South Africa
          14.2.4. Rest of MEA
    14.3. Market Size (USD Million) Forecast for MEA 2022-2028

15. Market Share Analysis and Competitive Landscape   
    15.1. Global Landscape - Key Players, Revenue and Presence
    15.2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
    15.3. Global Emerging Companies
    15.4. North America - Market Share Analysis and Key Regional Players
    15.5. Europe - Market Share Analysis and Key Regional Players
    15.6. Asia Pacific - Market Share Analysis and Key Regional Players
    15.7. Global Key Player - Growth Matrix

16. Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
         16.1. Biogen
                16.1.1. Company Overview
                16.1.2. Product Portfolio
                16.1.3. SWOT Analysis
                16.1.4. Financial Overview
                16.1.5. Strategic Overview
         16.2. Teva Pharmaceutical
                16.2.1. Company Overview
                16.2.2. Product Portfolio
                16.2.3. SWOT Analysis
                16.2.4. Financial Overview
                16.2.5. Strategic Overview
         16.3. Merck KGaA
                16.3.1. Company Overview
                16.3.2. Product Portfolio
                16.3.3. SWOT Analysis
                16.3.4. Financial Overview
                16.3.5. Strategic Overview
         16.4. Novartis
                16.4.1. Company Overview
                16.4.2. Product Portfolio
                16.4.3. SWOT Analysis
                16.4.4. Financial Overview
                16.4.5. Strategic Overview
         16.5. Bayer
                16.5.1. Company Overview
                16.5.2. Product Portfolio
                16.5.3. SWOT Analysis
                16.5.4. Financial Overview
                16.5.5. Strategic Overview
         16.6. Sanofi
                16.6.1. Company Overview
                16.6.2. Product Portfolio
                16.6.3.  SWOT Analysis
                16.6.4. Financial Overview
                16.6.5. Strategic Overview
         16.7. Acorda Therapeutics
                16.7.1. Company Overview
                16.7.2. Product Portfolio
                16.7.3. SWOT Analysis
                16.7.4. Financial Overview
                16.7.5. Strategic Overview
         16.8. Questcor Pharmaceuticals
                16.8.1. Company Overview
                16.8.2. Product Portfolio
                16.8.3. SWOT Analysis
                16.8.4. Financial Overview
                16.8.5. Strategic Overview
         16.9. Pfizer
                16.9.1. Company Overview
                16.9.2. Product Portfolio
                16.9.3. SWOT Analysis
                16.9.4. Financial Overview
                16.9.5. Strategic Overview
         16.10. Merck & Co
                16.10.1. Company Overview
                16.10.2. Product Portfolio
                16.10.3. SWOT Analysis
                16.10.4. Financial Overview
                16.10.5. Strategic Overview
          16.11. F.Hoffmann-La Roche Ltd
                16.11.1. Company Overview
                16.11.2. Product Portfolio
                16.11.3. SWOT Analysis
                16.11.4. Financial Overview
                16.11.5. Strategic Overview
          16.12. Bristol
                16.12.1. Company Overview
                16.12.2. Product Portfolio
                16.12.3. SWOT Analysis
                16.12.4. Financial Overview
                16.12.5. Strategic Overview

17. Pre and Post COVID-19 Impact
    17.1. Positive influence on the healthcare industry
    17.2. The financial disruption of the manufacturing sector
    17.3. Impact of COVID-19 on emerging companies
    17.4. Significant mandates in the regulations initiated by healthcare administrations
    17.5. The overall economic slowdown of the developing and developed nations

18. FutureWise SME Key Takeaway Points for Client

Tables

Figures